Cellectis stock tumbles after Barclays double downgrade

Cellectis SA (CLLS) shares dropped 14.6% after Barclays downgraded the stock to Underweight, cutting its price target to $1.30 from $9.00. Analyst Lukas Shumway cited lack of conviction in Cellectis' new programs, assigning negative net present values to .HEAL-101 and .HEAL-201. The valuation model now includes $2 each for Royalties and Milestones, -$1 for Debt, and $5 for Cash, assuming a capital raise in late 2027.

Original reporting
Published Sep 16, 2026, 3:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 3:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$CLLS
Bearish
high confidence
Mentioned
$CLLS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CLLSBearishHigh
01

Why it matters

The downgrade sharply reduces valuation expectations, likely prompting sell orders.

02

Market read

The downgrade drives a notable price move and may affect sentiment in the biotech sector.

03

What to watch

Potential upcoming clinical data for .HEAL‑101 could mitigate downside if positive.

Relevance 7/10Novelty 8/10Timing: same-day reaction

Background

Cellectis is a gene‑editing company listed on NASDAQ; recent analyst coverage has been mixed.

Company-level read

Ticker impact

$CLLSBearishHigh confidence
Context

Barclays downgraded CLLS to Underweight and cut the price target to $1.30, triggering a 14.6% share drop.

Expected impact

Further short-term decline as investors reassess valuation.

Evidence & confidence

Analyst removed valuation for key programs and lowered cash assumptions, indicating weak outlook.

Market effects

Negative sentiment may spill to other gene‑editing and biotech stocks.

Limited to US biotech sector.

Minimal global impact beyond niche biotech investors.

Counterpoint

If the downgrade overstates risks, the stock could rebound on short‑covering.

Key entities

  • Barclays

    Issued the downgrade and target cut.

Related articles

$CLLSMedAI 8/10

Cellectis Earnings Call Highlights In Vivo Editing Shift

Cellectis (CLLS) reported Q3 earnings, highlighting a shift to in vivo gene editing. Preclinical results for HEAL-101 and HEAL-201 showed promise, with HEAL-101 reducing APOC3 levels by 67% and triglycerides by 76% in mice. The company expects clinical data in 2027-2028. Revenue fell to $19.9M, but net income improved to a $5.2M gain. Cash runway extends into 2H 2028. Management also announced workforce reductions and discontinued legacy programs.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$CLLSMed

What Cellectis (CLLS) Said on Its Q3 Earnings Call

Cellectis (CLLS) reported Q3 earnings, highlighting HEAL-201's potential in reducing PCSK9 levels and plans for a Phase 1 trial. The company expects to cut global headcount by up to 70% in 2026-2027. Revenues fell to $19.9M from $67.4M YoY, while R&D expenses rose to $108.8M. Cash reserves were $149M as of Sept. 30, down from $211M at the end of 2025.

$CLLSMedAI 8/10

Cellectis Reports Third-Quarter 2026 Results and In Vivo Editing Data

Cellectis SA reported Q3 2026 results with $149M in cash, $19.9M revenue (down from $67.4M), and increased R&D expenses to $108.8M. Preclinical data showed promising results for .HEAL-101 and .HEAL-201. The company is shifting focus to in vivo gene editing, discontinuing lasme-cel and eti-cel programs. Analysts rate CLLS stock as Buy with $8.00 target, while TipRanks' AI rates it Neutral.